Discovery of novel druggable binding pockets on SARS-CoV-2 PLpro via fragment screening and insights for structure-based inhibitor design
Journal of Biological Chemistry · 2026
DOI: 10.1016/j.jbc.2026.113453 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Tingting Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Facility for Protein Science in Shanghai, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, People's Republic of …. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, Drug Design, Protease Inhibitors. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Chinese Academy of Sciences Key Technology Talent Program, Chinese Academy of Sciences.
Abstract (Originalsprache)
Coronaviruses are a large family of viruses capable of causing severe respiratory diseases, with recent outbreaks posing major threats to global public health. The SARS-CoV-2 papain-like protease (PLpro) is an essential viral enzyme involved in viral replication and host immune evasion, making it an attractive target for antiviral drug development. However, no PLpro-targeted drugs have yet been approved. Here, we employed a fragment-based drug discovery (FBDD) strategy combined with crystallographic screening and identified 23 fragment compounds with well-defined electron density. These fragments bind to seven distinct sites on PLpro and reveal multiple compound scaffolds and potential binding pockets through systematic structural analysis. Notably, Site 2 represents a newly identified pocket adjacent to the canonical substrate-binding site (Site 1) and shows strong potential for fragment linking to enable inhibitor optimization. Among them, Frag368 exhibited good enzyme inhibitory activity. Furthermore, based on structural similarities among the fragments, the FDA-approved drug 5-fluorouracil was identified as a ligand for Site 2. Biochemical assays confirmed that 5-fluorouracil exhibits inhibitory activity against PLpro. Collectively, these findings provide a robust structural framework for the rational design of PLpro inhibitors and support the development of novel antiviral therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Facility for Protein Science in Shanghai, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, People's Republic of China; University of Chinese Academy of Sciences, Beijing, People's Re…
- National Facility for Protein Science in Shanghai, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, People's Republic of China; College of Life Sciences, Shanghai Normal University, Shanghai,…
- National Facility for Protein Science in Shanghai, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, People's Republic of China.
Förderung
- National Natural Science Foundation of China
- Chinese Academy of Sciences Key Technology Talent Program
- Chinese Academy of Sciences
- Shanghai Municipal Natural Science Foundation
Zitieren
APA
Wu, T., Zhou, Z., Li, X., Wang, W., Zhang, H., Qin, W., & Xiao, Q. (2026). Discovery of novel druggable binding pockets on SARS-CoV-2 PLpro via fragment screening and insights for structure-based inhibitor design. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2026.113453
Vancouver
Wu T, Zhou Z, Li X, Wang W, Zhang H, Qin W, et al. Discovery of novel druggable binding pockets on SARS-CoV-2 PLpro via fragment screening and insights for structure-based inhibitor design. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2026.113453
BibTeX
@article{Wu2026,
author = {Wu, Tingting and Zhou, Zhenghua and Li, Xingyu and Wang, Weihua and Zhang, Haijiao and Qin, Wenming and Xiao, Qingjie},
title = {Discovery of novel druggable binding pockets on SARS-CoV-2 PLpro via fragment screening and insights for structure-based inhibitor design},
journal = {Journal of Biological Chemistry},
year = {2026},
doi = {10.1016/j.jbc.2026.113453}
}
EUVIMED